A specific vaccine effective against stage I and stage II malignant disease in guinea pigs. Effect of variations in preparations and storage
- PMID: 6965232
- PMCID: PMC11039208
- DOI: 10.1007/BF00200174
A specific vaccine effective against stage I and stage II malignant disease in guinea pigs. Effect of variations in preparations and storage
Abstract
Guinea pigs, each with an established, syngeneic dermal line 10 tumor and lymph node metastases, were immunized by intradermal injection of a mixture of irradiated line 10 cells and an emulsion containing heat-killed BCG. Immunization eradicated 7- or 10-day-old dermal tumors (about 10 or 12 mm in diameter, respectively) and prevented growth of microscopic lymph node metastases. Fourteen-day-old dermal tumors (about 15 mm in diameter) were not rejected by immunization. Guinea pigs with stage II disease (21-day-old dermal tumors and palpable metastases in the first draining lymph node) were treated by excision of the dermal tumor and the first draining lymph node, and by specific immunization. This treatment eliminated tumor cells remaining in the second draining lymph nodes. The surgical treatment alone was not curative, palpable metastases in the second draining lymph nodes progressed and the animals died (some with visible lung metastases). Emulsions containing killed BCG were good adjuvants even after prolonged storage at 4 degrees C, but lost most of their adjuvant activity after autoclaving or freezing.
Similar articles
-
Eradication by active specific immunotherapy of established tumor transplants and microscopic lymph node metastases.Cancer Res. 1982 Jul;42(7):2544-6. Cancer Res. 1982. PMID: 7083146
-
Regression by active specific immunotherapy of established dermal tumor transplants and lymph node metastases in guinea pigs.Infect Immun. 1981 Jan;31(1):514-6. doi: 10.1128/iai.31.1.514-516.1981. Infect Immun. 1981. PMID: 7216457 Free PMC article.
-
Treatment by limited surgery and specific immunization of guinea pigs with stage II experimental cancer.J Exp Med. 1981 Aug 1;154(2):253-61. doi: 10.1084/jem.154.2.253. J Exp Med. 1981. PMID: 7264559 Free PMC article.
-
Mechanism of BCG induced regression of line 10 hepatocarcinoma in the guinea pig.In Vivo. 1991 Nov-Dec;5(6):655-61. In Vivo. 1991. PMID: 1810452 Review.
-
Histological evaluation of immunologically mediated tumor regression of the line 10 guinea pig hepatocarcinoma.Virchows Arch B Cell Pathol Incl Mol Pathol. 1986;50(3):249-69. doi: 10.1007/BF02889905. Virchows Arch B Cell Pathol Incl Mol Pathol. 1986. PMID: 2870577 Review.
References
-
- Ashley MP, Zbar B, Hunter JT, Rapp HJ, Sugimoto T. Adjuvant-antigen requirements for active specific immunotherapy of microscopic metastases remaining after surgery. Cancer Res. 1980;40:4197. - PubMed
-
- Bartlett GL, Zbar B. Tumor-specific vaccine containing Mycobacterium bovis and tumor cells: safety and efficacy. J Natl Cancer Inst. 1972;48:1709. - PubMed
-
- Bartlett GL, Zbar B. Adjuvants for tumor-specific vaccine: Bordetella pertussis or mycobacterial cell walls attached to oil droplets. J Natl Cancer Inst. 1973;50:1385. - PubMed
-
- Bekierkunst KA. Immunotherapy and vaccination against cancer with nonliving BCG and cord factor (trehalose-6,6'-dimycolate) Int J Cancer. 1975;16:442. - PubMed
-
- Hanna MG, Peters LC. 22nd Annual Clinical Conference on Cancer, The University of Texas System Cancer Center M.D. Anderson Hospital and Tumor Institute. Immunotherapy of human cancer. New York: Raven Press; 1978. BCG immunotherapy: Efficacy of BCG-induced tumor immunity in guinea pigs with regional tumor and/or visceral micrometastases; p. 111.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources